Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors-Reference-Cited by-同舟云学术

Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors

Published:2011-08-24 Issue:12 Volume:50 Page:1021-1032
ISSN:1045-2257
Container-title:Genes, Chromosomes and Cancer
language:en
Short-container-title:Genes Chromosom. Cancer

Author:

Beert Eline,Brems Hilde,Daniëls Bruno,De Wever Ivo,Van Calenbergh Frank,Schoenaers Joseph,Debiec-Rychter Maria,Gevaert Olivier,De Raedt Thomas,Van Den Bruel Annick,de Ravel Thomy,Cichowski Karen,Kluwe Lan,Mautner Victor,Sciot Raf,Legius Eric

Publisher

Wiley

Subject

Cancer Research,Genetics

Reference38 articles.

1. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors;Birindelli;Lab Invest,2001

2. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1;Brems;Lancet Oncol,2009

3. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations;Cawthon;Cell,1990

4. Elevated risk for MPNST in NF1 microdeletion patients;De Raedt;Am J Hum Genet,2003

5. Genomic organization of the NF1 microdeletion region;De Raedt;Genomics,2004

Cited by 200 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary Approach to Neurofibromatosis Type 1–Associated Malignant Peripheral Nerve Sheath Tumors;American Society of Clinical Oncology Educational Book;2024-06

2. Challenges in determining the malignant potential of atypical neurofibromas (aNF) using histopathologic features and the potential need for CDKN2A/2B testing: a case report;Journal of Translational Genetics and Genomics;2024-04-22

3. The NF1+/- Immune Microenvironment: Dueling Roles in Neurofibroma Development and Malignant Transformation;Cancers;2024-02-29

4. Malignant peripheral nerve sheath tumor — from genetics to multidisciplinary treatment;Oncology in Clinical Practice;2024-02-27

5. Epigenetic determinants in soft tissue sarcomas: molecular mechanisms and therapeutic targets;Expert Opinion on Therapeutic Targets;2024-01-26